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A quantitative high resolution computed tomography assessment of patients with
stable bronchiectasis
GC Ooi, PL Khong, *M Chan-Yeung, *JCM Ho, PKS Chan, JCK Lee, *WK Lam, *KW Tsang. Departments of Diagnostic
Radiology and Medicine, University of Hong Kong, Hong Kong SAR, China.
PURPOSE: To evaluate the clinical relevance of HRCT findings using a quantitative HRCT protocol to assess
severity of bronchial wall thickening, extent of bronchiectasis, and presence of small airway abnormalities and
mosaic pattern.
MATERIALS AND METHODS: Sixty Chinese with steady state bronchiectasis underwent thoracic HRCT scan
and full lung function tests. Exacerbation frequency/year and 24h-sputum volume were determined. Extent of
bronchiectasis, bronchial wall thickening, presence of small airway abnormalities and mosaic attenuation were
evaluated in each lobe, including lingula. Differences between sex and smoking status on HRCT, lung function and
clinical parameters were tested using either independent sample t-test or Mann-Whitney rank sum test. Spearman’s
correlation was used to evaluate associations between clinical, lung function and HRCT scores. Multiple regression
analyses were performed to determine HRCT parameters that best predict lung function and clinical parameters
adjusted for smoking.
RESULTS: Exacerbation frequency was associated with bronchial wall thickening (r=0.32, p=0.03); 24h sputum
volume with bronchial wall thickening, small airway abnormalities (r=0.30, 0.39, p<0.05), and FEV1, FEV1/FVC
and FEF25-75 (r=-0.33, -0.29, -0.32; p<0.05). Extent of bronchiectasis, bronchial wall thickening and mosaic
attenuation was respectively related to FEV1 (r=-0.43 to -0.60 p<0.001), FEF25-75 (r=-0.38 to -0.57; p<0.001), FVC
(r=-0.36 to -0.46, p<0.01), and FEV1/FVC (r=-0.31 to -0.49, p<0.01). After multiple regression bronchial wall
thickening remained a significant determinant of airflow obstruction, while small airway abnormalities remained
associated with 24h-sputum volume. Women in general had milder disease than men, but showed more HRCT-
functional correlations.
CONCLUSIONS: This study has established a link between morphologic HCRT parameters and clinical activity,
and emphasised the role of BWT in bronchiectasis.
Inhaled corticosteroid therapy in bronchiectasis—a 12-month study
Tsang KW, Ho PL, Tan KC, GC Ooi, Ho JC, Tipoe GL, Wu AY, Ip MS, Lam WK, Chan-Yeung M.
University Departments of Medicine, Microbiology, Anatomy, and Diagnostic Radiology, University of Hong Kong, Hong
Kong SAR.
Background: The clinical efficacy of inhaled corticosteroid (ICS) therapy has not been evaluated on patients with
bronchiectasis, despite the presence of chronic airway inflammation in this condition. We have, therefore,
performed a double-blind randomized study on patients with stable bronchiectasis.
Methods: After a baseline follow up of 3 consecutive weekly visits, 86 patients were randomised to receive either
fluticasone 500µg BID (n=43, 23F, 57.7±14.35 yr) or matched placebo (n=43, 34F, 59.2±14.16 yr), and reviewed
regularly for 52 weeks.
Findings: Altogether 35 and 38 patients from the fluticasone and placebo groups completed the study respectively.
Compared with placebo, ICS therapy was associated with significantly more patients showing improvement in 24h
sputum volume (OR 2.5, 95%CI 1.1-6.0), but not exacerbation frequency, FEV1, FVC or sputum purulence score.
Significantly more fluticasone patients with Ps. aeruginosa infection at baseline had improvement in 24h sputum
volume (OR 13.3, 95%CI 1.8-100.1) and exacerbation frequency (OR 13.5, 95%CI 1.8-101.1), compared with
their placebo counterparts. Other predictors for improvement in post-treatment 24h sputum volume with fluticasone
therapy include baseline 24h sputum volume <30ml (OR 2.7, 95%CI 1.1-6.7), exacerbation frequency ≤2/yr
(OR 5.1, 95%CI 1.2-22.7), and sputum purulence score >5 (OR 2.7, 95%CI 1.0-6.9). Both groups of patients
had improvement in respiratory symptoms after treatment, but ICS therapy was associated with significantly
less patients complaining of cough (p=0.03).
Interpretation: Our results show that inhaled corticosteroid therapy, over a 52-week duration, is clinically benefi-
cial to patients with bronchiectasis, particularly those with Ps. aerurginosa infection
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